Serum OX40 Ligand as a Biochemical Regulator of Th2-Dominant Immune Activation in Asthma: An Integrated Cytokine Network Analysis
Serum OX40L and Immune Activation in Asthma
Abstract
Background: Asthma is characterized by complex immune dysregulation involving coordinated cytokine and chemokine networks. OX40 ligand (OX40L), a key T-cell co-stimulatory molecule, has been implicated in Th2-mediated inflammation; however, its serum-level biochemical interactions with immune activation pathways in asthma remain incompletely defined.
Methods: In this cross-sectional study, serum OX40L and immune activation-related factors were quantified in 82 patients with asthma and 40 healthy controls. Multiplex cytokine analysis was performed to measure Th2-, Th17-, pro- and anti-inflammatory mediators, along with chemokines and total IgE. Lung function indices were assessed by spirometry. Correlation analysis and multivariable linear regression were applied to identify immune factors independently associated with serum OX40L levels.
Results: Serum OX40L concentrations were significantly elevated in asthma patients compared with controls and increased progressively with disease severity (all P<0.001). OX40L exhibited strong positive correlations with Th2-associated cytokines, particularly interleukin-5 (IL-5; r=0.75, P<0.001), and chemokines, while showing a significant inverse association with the anti-inflammatory cytokine IL-10. OX40L levels were also negatively correlated with forced expiratory volume in one second (FEV1%pred; r=-0.72, P<0.001). Multivariable regression identified IL-5 (β=0.35), FEV1%pred (β=-0.28), and annual exacerbation frequency (β=0.22) as independent biochemical determinants of serum OX40L, collectively explaining 68.3% of its variance.
Conclusion: Serum OX40L is closely integrated within the Th2-dominant immune activation network in asthma and reflects both immune imbalance and functional airway impairment. These findings support OX40L as a biochemically relevant indicator of immune activation intensity and highlight its potential role within cytokine-driven regulatory pathways in asthma.
References
2. Grunwell JR, Fitzpatrick AM. Asthma Phenotypes and Biomarkers. Resp Care 2025; 70(6): 649-74.
3. Cox JK, Lockey R, Cardet JC. Cough-Variant Asthma: A Review of Clinical Characteristics, Diagnosis, and Pathophysiology. The Journal of Allergy and Clinical Immunology. In Practice 2025; 13(3): 490-8.
4. Hammad H, Ahmed E, Lambrecht BN. Immunotherapy for asthma. Cell Mol Immunol 2025; 22(12): 1521-32.
5. Rhoads SL, Seluk L, Wechsler ME. Asthma therapeutics: Past, present, and future. Pharmacol Rev 2025; 77(4): 100062.
6. Qian G, Jiang W, Sun D, Sun Z, Chen A, Fang H, et al. B-cell-derived IL-10 promotes allergic sensitization in asthma regulated by Bcl-3. Cell Mol Immunol 2023; 20(11): 1313-27.
7. Papadopoulos NG, Bacharier LB, Jackson DJ, Deschildre A, Phipatanakul W, Szefler SJ, et al. Type 2 Inflammation and Asthma in Children: A Narrative Review. The Journal of Allergy and Clinical Immunology. In Practice 2024; 12(9): 2310-24.
8. Bryant N, Muehling LM. T-cell responses in asthma exacerbations. Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma, & Immunology 2022; 129(6): 709-18.
9. Lee S, Le DD, Bae C, Park JW, Lee M, Cho S, et al. Oleic acid attenuates asthma pathogenesis via Th1/Th2 immune cell modulation, TLR3/4-NF-κB-related inflammation suppression, and intrinsic apoptotic pathway induction. Front Immunol 2024; 15: 1429591.
10. Zhang B, Zeng M, Zhang Q, Wang R, Jia J, Cao B, et al. Ephedrae Herba polysaccharides inhibit the inflammation of ovalbumin induced asthma by regulating Th1/Th2 and Th17/Treg cell immune imbalance. Mol Immunol 2022; 152: 14-26.
11. Camargo LDN, Righetti RF, de Almeida FM, Dos Santos TM, Fukuzaki S, Martins NAB, et al. Modulating asthma-COPD overlap responses with IL-17 inhibition. Front Immunol 2023; 14: 1271342.
12. Gallagher K, Halperin-Goldstein S, Paller AS. New treatments in atopic dermatitis update. Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma, & Immunology 2025; 135(5): 498-510.
13. Seluk L, Davis AE, Rhoads S, Wechsler ME. Novel asthma treatments: Advancing beyond approved novel step-up therapies for asthma. Annals of Allergy, Asthma & Immunology: Official Publication of the American College of Allergy, Asthma, & Immunology 2025; 134(1): 9-18.
14. Song R, Zhang H, Liang Z. Research progress in OX40/OX40L in allergic diseases. Int Forum Allergy Rh 2024; 14(12): 1921-8.
15. Sethi GS, Ramamoorthy Premlal AL, Chawla A, Croft M. ICOSL, OX40L, and CD30L control persistence of asthmatic CD4 tissue-resident memory CD4 T cells. The Journal of Allergy and Clinical Immunology 2025; 155(6): 1993-2008.
16. Ishmael L, Casale T, Cardet JC. Molecular Pathways and Potential Therapeutic Targets of Refractory Asthma. Biology-Basel 2024; 13(8): 583.
17. Hoshino A, Tanaka Y, Akiba H, Asakura Y, Mita Y, Sakurai T, et al. Critical role for OX40 ligand in the development of pathogenic Th2 cells in a murine model of asthma. Eur J Immunol 2003; 33(4): 861-9.
18. Huang L, Wang M, Yan Y, Gu W, Zhang X, Tan J, et al. OX40L induces helper T cell differentiation during cell immunity of asthma through PI3K/AKT and P38 MAPK signaling pathway. J Transl Med 2018; 16(1): 74.
19. Zhou Y, Huang X, Yu H, Shi H, Chen M, Song J, et al. TMT-based quantitative proteomics revealed protective efficacy of Icariside II against airway inflammation and remodeling via inhibiting LAMP2, CTSD and CTSS expression in OVA-induced chronic asthma mice. Phytomedicine: International Journal of Phytotherapy and Phytopharmacology 2023; 118: 154941.
Copyright (c) 2026 Ziyi Zhu, Shumin Li
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.